Equity intelligence report • June 03, 2026
Elevance Health, formerly Anthem, is navigating a complex landscape marked by fluctuating financial performance and strategic adjustments. Recently, the company reported first-quarter 2026 revenues of $49.5 billion and adjusted EPS of $12.58, exceeding forecasts and prompting an increase in its full-year EPS guidance to at least $26.75. However, ongoing challenges remain, including a projected negative Medicaid margin of -1.75% and significant compliance issues. Despite these pressures, Elevance has initiated a $1.1 billion stock repurchase program and received a positive upgrade from Bank of America following strong earnings results. The healthcare provider continues to face scrutiny from analysts amid mixed market sentiments and a rising benefit expense ratio.
Click a month on the chart to update the report below.
